Cryo-Cell International I... (CCEL)
| Bid | 4.46 |
| Market Cap | 53.02M |
| Revenue (ttm) | 31.8M |
| Net Income (ttm) | 399.7K |
| EPS (ttm) | 0.05 |
| PE Ratio (ttm) | 131.2 |
| Forward PE | 62.33 |
| Analyst | Buy |
| Ask | 7.47 |
| Volume | 4,614 |
| Avg. Volume (20D) | 15,142 |
| Open | 6.56 |
| Previous Close | 6.30 |
| Day's Range | 6.20 - 6.56 |
| 52-Week Range | 5.75 - 9.50 |
| Beta | 0.64 |
About CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto...
Analyst Forecast
According to 1 analyst ratings, the average rating for CCEL stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 29.57% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...
